Prevalence, incidence, and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning models - Takeaways - MDSpire

Prevalence, incidence, and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning models

  • By

  • Reinier C A van Linschoten

  • Nikki van Leeuwen

  • David van Klaveren

  • Marieke J Pierik

  • Rob Creemers

  • Evelien M B Hendrix

  • Jan A Hazelzet

  • C Janneke van der Woude

  • Rachel L West

  • Desirée van Noord

  • February 13, 2025

  • 0 min

Share

  • 1

    Machine learning models were developed to identify inflammatory bowel disease (IBD) cases in administrative data in the Netherlands.

  • 2

    The prevalence of IBD in the Netherlands was found to be 577.6 per 100,000 as of December 31, 2020, with regional variations.

  • 3

    The incidence of IBD was stable at 20.1 per 100,000 in 2020, indicating a slower increase in prevalence than previously expected.

  • 4

    Mortality rates for IBD patients rose to 11.6 per 1,000 in 2020, higher than the general population's rate of 9.5.

  • 5

    The random forest model demonstrated the highest accuracy for identifying IBD cases, achieving an AUC of 0.97.

Original Source(s)

Prevalence, incidence, and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning models

  • by Reinier C A van Linschoten, Nikki van Leeuwen, David van Klaveren, Marieke J Pierik, Rob Creemers, Evelien M B Hendrix, Jan A Hazelzet, C Janneke van der Woude, Rachel L West, Desirée van Noord

  • February 13, 2025

Related Content

Metabolic and Structural Alterations Linked to Mice's Vulnerability to Primary Echinostoma caproni Infections

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.